IP Library Granted Patent US 9,090,933
Granted Patent B2
US 9,090,933 · App. 14/202,919 · Granted Jul 28, 2015

Cancer screening by detection of ultrastructural and molecular markers

Inventors: Vadim Backman (Chicago, IL); Hariharan Subramanian (Chicago, IL); Dhwanil Damania (Evanston, IL); Hemant Roy (Highland Park, IL); Dhananjay Kunte (Vernon Hills, IL); Mart Angelo De la Cruz (Niles, IL)
Assignees: Northwestern University; Northshore University Healthsystem
C12Q1/6806C12Q1/6886G01N21/41G01N33/57407G01N33/57411G01N33/57419G01N33/57484C12Q2600/158C12Q2600/178G01N21/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,933
App. No.
14/202,919
Granted
Jul 28, 2015
Kind
B2
Abstract

The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject.

Claims (18)

1. A method of isolating mucus layer colonocytes from a stool sample comprising:

(a) gently agitating the stool sample in a wash solution;

(c) centrifuging the stool sample in the wash solution to form a cell pellet;

(d) disrupting the cell pellet in a cell preservation solution to form a resuspended cell pellet;

(e) filtering the resuspended cell pellet through a first strainer and collecting supernatant;

(f) filtering the supernatant through a second strainer to retain mucus layer colonocytes; and

(g) combining the mucus layer colonocytes with at least one mucolytic agent and at least one chelating agent to form a suspension of isolated mucus layer colonocytes.

2. The method of claim 1 wherein the wash solution contains ammonium thioglycolate.

3. The method of claim 1 wherein the first strainer is a filter of about 300 μM.

4. The method of claim 1 wherein the second strainer is a filter of about 125 μM.

5. The method of claim 1 wherein the at least one mucolytic agent is N-acetyl L-cysteine (NALC).

6. The method of claim 5 wherein the NALC comprises about 0.5 mol/L NALC.

7. The method of claim 5 wherein the EDTA comprises about 0.0015 mol/L EDTA.

8. The method of claim 1 wherein the at least one chelating agent is ethylene diaminetetraacetic acid (EDTA).

9. The method of claim 1 further comprising applying the suspension of isolated mucus layer colonocytes to a slide.

10. The method of claim 9 wherein the mucus layer colonocytes are applied to the slide using an automated slide preparation unit.

11. The method of claim 9 wherein the mucus layer colonocytes are preserved with ethanol.

12. The method of claim 1 further comprising analyzing RNA expression in the mucus layer colonocytes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: BACKMAN, VADIM; SUBRAMANIAN, HARIHARAN; DAMANIA, DHWANIL
To: NORTHWESTERN UNIVERSITY
Reel/Frame 036266/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: ROY, HEMANT; KUNTE, DHANANJAY; DE LA CRUZ, MART
To: NORTHSHORE UNIVERSITY HEALTHSYSTEM
Reel/Frame 036266/0548 →
CONFIRMATORY LICENSE Recorded Apr 9, 2014
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032641/0430 →
Continuity (3)
Continuation 13399706 · Feb 17, 2012
Provisional Application 61443912 · Feb 17, 2011
Related Publication 20140302514A1 · Oct 9, 2014